GlassScriptPhysician profile
Emmanuel Nwapa
NPI 1922107788
$6,613.36
in general payments reported to CMS, 2019-2025
27 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $731 · 2021: $583 · 2022: $644 · 2023: $651 · 2024: $919 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,189.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $977.19 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $916.46 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $850.66 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $548.69 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $547.49 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $352.68 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Allergan, INC. | $270.56 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $246.37 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $215.70 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $214.90 | 2019-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $190.25 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $176.37 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $172.47 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $139.17 | 2020-2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $135.40 | 2020-2025 | Uzedy, Austedo Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $126.83 | 2019 | |
| Corium, LLC | $104.93 | 2021-2024 | Azstarys |
| Neos Therapeutics, LP | $77.94 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $76.99 | 2021-2025 | Qelbree |
| Axsome Therapeutics, INC. | $60.76 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $51.26 | 2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $50.30 | 2019 | |
| Avion Pharmaceuticals | $36.78 | 2023 | Methylphenidate Hydrochloride |
| Sage Therapeutics, LLC | $22.79 | 2025 | Zurzuvae |
| Eisai INC. | $17.56 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.65 | 2019 | |
| Owp Pharmaceuticals, INC. | $16.21 | 2025 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Nwapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.